BIIB - BIOGEN INC.
IEX Last Trade
149.9
0.240 0.160%
Share volume: 32,821
Last Updated: Thu 26 Dec 2024 08:29:57 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$149.66
0.24
0.16%
Fundamental analysis
36%
Profitability
38%
Dept financing
13%
Liquidity
24%
Performance
43%
Performance
5 Days
-0.24%
1 Month
-5.50%
3 Months
-23.03%
6 Months
-33.61%
1 Year
-42.84%
2 Year
-45.77%
Key data
Stock price
$149.90
DAY RANGE
$148.14 - $150.64
52 WEEK RANGE
$147.85 - $268.30
52 WEEK CHANGE
-$42.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Christopher A. Viehbacher
Region: US
Website: biogen.com
Employees: 8,720
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: biogen.com
Employees: 8,720
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. It also offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and pemphigus vulgaris.
Recent news